Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial

Atherosclerosis

Volumn 160, Issue 1, 2002, Pages 41-48

  Otvos, James D ^a,b   Shalaurova, Irina ^a,b   Freedman, David S ^c   Rosenson, Robert S ^d  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b LIPOSCIENCE INC   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CHD risk; HMG CoA reductase inhibitors; Lipoprotein subclasses; Small LDL

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036146056     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00544-5     Document Type: Article

References (40)

1. Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction
2. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease
3. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk
4. Characterization of low-density lipoprotein subclasses: Methodologic approaches and clinical relevance
5. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia
6. Pravastatin effectively lowers LDL cholesterol in familial combines hyperlipidemia without changing LDL subclass pattern
7. Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size
8. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease
9. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
10. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement
11. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
12. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins
13. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B
14. Hepatic lipase influences high density lipoprotein subclass distribution in normotriglyceridemic men: Genetic and pharmacological evidence
15. Low-density lipoprotein subclass patterns and risk of myocardial infarction
16. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease
17. Characterization of plasma low density lipoproteins of nonhuman primates fed dietary cholesterol
18. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction
19. Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women
20. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease
21. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men
22. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects
23. Cellular consequences of the associations of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis
24. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease
25. Intermediate-density lipoproteins and progression of coronary disease in hypercholesterolaemic men
26. Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression
27. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
28. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: Lipid and nonlipid factors
29. Did grandma give you heart disease? The new battle against coronary artery disease
30. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability
31. A comparative study of efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: Prediction of response by baseline lipids, apo E genotype, lipoprotein (a) and insulin
32. Effect of fluvastatin on low-density lipoprotein peak particle diameter
33. High density lipoproteins and coronary atherosclerosis: A strong inverse relation with the largest particles is confined to normotriglyceridemic patients
34. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease
35. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
36. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
37. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
38. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)